- Poster presentation
- Open Access
Therapy with teicoplanin in the ICU: continuous intravenous infusion or intermittent intravenous administration?
© BioMed Central Ltd 2008
- Published: 13 March 2008
- Maintenance Dose
- Therapeutic Drug Monitoring
- Continuous Intravenous Infusion
Teicoplanin is a glycopeptide antibiotic. The principle pharmacodynamic parameter is time dependency.
A total of 16 critically ill patients were enrolled into the study after informed consent. They were being treated for suspected or documented Gram-positive infections. We administrated an initial loading dose of 10 mg/kg every 12 hour for three doses, followed by a maintenance dose based on therapeutic drug monitoring and therapy personalization by Bayesian computerized software. For the maintenance dose we divided patients into two groups; in the first group teicoplanin was administrated intermittently every 24 hours (control group), in the second group by continuous infusion (study group). Adequate drug exposure was defined as a plasma level concentration >10 mg/l or greater. Blood samples for therapeutic drug monitoring were collected immediately before teicoplanin administration. When the pathogen agents were isolated, bacteriostatic and bactericidial properties of the serum were tested in both groups.
Our data suggest that the administration of teicoplanin by continuous intravenous infusion compared with the intermittent mode might be more efficient in critically ill patients.
This article is published under license to BioMed Central Ltd.